Project Grant R01CA279679
Award Date
9/3/24
Completion Date
8/31/28
Dollars Obligated
$543K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Bloomington, IN 47405, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will fund a research project titled "SESAME: SUN EXPOSURE AND ACTIVITIES AFTER SKIN CANCER: OPTIMIZATION OF MHEALTH INTERVENTIONS". The $331,781 award, effective September 13, 2024 through August 31, 2027, will support Northwestern University in refining and enhancing intervention tools, including a mobile app, to reduce unprotected sun exposure and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $706,771 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct a hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in Federally Qualified Health Centers in Tampa, Florida. The study aims to evaluate the impact of a precision prevention intervention to improve skin cancer prevention behaviors, such as...
The federal Project Grant award of $1,187,274.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant is supporting research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The research project aims to develop novel, plant-derived compounds that can serve as...
This $958,434 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The Leland Stanford Junior University to elucidate the molecular mechanisms of RET kinase regulation in human epidermis and define RET-regulated impacts on the tumor immune microenvironment. The long-term goal is to develop topical selective RET inhibitors for effective therapeutic prevention of cutaneous squamous cell carcinoma (CSCC). The proposed research...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a research project to identify key features of e-cigarette-related social media posts that are associated with high user engagement. The goal is to provide guidance for designing effective vaping prevention messages for future public health campaigns to help communicate the risks of e-cigarette use and prevent youth and young adult initiation...
This $290,052 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports the development and evaluation of a mobile-optimized intervention called PERCS-YA (Personalized Cancer Support for Young Adults) to reduce worry and distress among young adult cancer survivors. The award will fund stakeholder-engaged refinement of the PERCS-YA intervention, followed by a Phase II efficacy trial utilizing both a...
The National Cancer Institute (NCI) awarded a $1,019,013 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to the Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The overarching goal is to study the early stages of skin cancer development, including melanoma and cutaneous squamous cell carcinoma, and the role of the immune system in this transition from pre-cancer to cancer. The...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) will fund the development and evaluation of smoking health communications targeted to adults who smoke nondaily (ASN). The $164,484 award, effective August 11, 2025 through July 31, 2027, will support two main aims: Developing and iteratively refining smoking cessation messages for ASN that vary in affective valence (positive vs. negative) and type of consequences (social vs....